We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mast-Cell Stabilizing Effects of Olopatadine

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00389025
First Posted: October 17, 2006
Last Update Posted: November 22, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Alcon Research
  Purpose
To assess the effects of olopatadine of the release of mast cell histamine

Condition Intervention Phase
Allergic Conjunctivitis Drug: Olopatadine (generic name) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Mast-Cell Stabilizing Effects of Olopatadine

Resource links provided by NLM:


Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Tear histamine

Secondary Outcome Measures:
  • Tear cytology, subject evaluation of ocular itching, investigators evaluation of ocular redness

Enrollment: 24
Study Start Date: October 2006
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Asymptomatic and not using any topical or systemic medication

Exclusion Criteria:

  • Age
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00389025


Locations
Italy
Padova Site
Padova, Italy
Sponsors and Collaborators
Alcon Research
Investigators
Study Director: Terry Wiernas Alcon Research
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00389025     History of Changes
Other Study ID Numbers: C-05-30
First Submitted: October 13, 2006
First Posted: October 17, 2006
Last Update Posted: November 22, 2016
Last Verified: January 2010

Keywords provided by Alcon Research:
Subject with clinical history of seasonal allergic conjunctivitis

Additional relevant MeSH terms:
Conjunctivitis
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Olopatadine Hydrochloride
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Anti-Allergic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action